Excelerate Energy Delivers Strong Second Quarter 2023 Results
THE WOODLANDS, Texas–(BUSINESS WIRE)–Excelerate Energy, Inc. (NYSE: EE) (the “Company” or “Excelerate”) today reported its…
News
Atlas Global Brands Provides Update on Delay in Filing Annual and Interim Financial Statements
CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Aug. 09, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc….
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or…
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
The Company remains committed to its goal of bringing avasopasem to patients and intends to…
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues…
Certara Reports Second Quarter 2023 Financial Results
Provides Update to Full Year 2023 Financial Guidance PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE)…
Nephros Announces Results for Quarter Ended June 30, 2023
Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022;Year-to-Date Revenue Increases 45%; Maintains…
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update
TARRYTOWN, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Company expects its cash and cash equivalents will continue to fund operations into late 2024…
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance…
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing…
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
— Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer…
electroCore Announces Second Quarter 2023 Financial Results
Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter…
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in…
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular…
Surrozen Provides Second Quarter 2023 Financial Results
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers…
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4…
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
– Dutch Ministry of Health Approves VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce the Risk of…